# First Report of Ethylenediaminetetraacetic Acid-Dependent Pseudo-Thrombocytopenia in Chile: Prevalence and Laboratory Insights

## TL;DR

This study reports the first prevalence of EDTA-dependent pseudo-thrombocytopenia in Chile and suggests citrate tubes can provide accurate platelet counts.

## Contribution

The first report of EDTA-PCTP prevalence in Chile and a comparison of citrate and EDTA tubes for platelet counting.

## Key findings

- The prevalence of EDTA-PCTP was 0.044% in southern Chile over 4 years.
- Platelet counts from citrate tubes after 2–5 hours matched EDTA tube counts at time 0.

## Abstract

Background: Ethylenediaminetetraacetic acid-dependent pseudo thrombocytopenia (EDTA-PCTP) is defined as a false in vitro decrease in the platelet count performed in the EDTA tube due to the spontaneous formation of platelet aggregates that prevent a correct count in hematological auto analyzers. The frequency of EDTA-PCTP varies depending on the population studied, ranging from 0.01% to 30.0%. In Chile, although the diagnosis of this condition is performed in clinical laboratories, only a few isolated reports have been described. Objectives: To determine the prevalence of EDTA-PCTP in a cohort of patients who attended an outpatient clinical laboratory in southern Chile over a period of almost 4 years. Methods: A retrospective analysis was conducted using the Laboratory Information System from January 2021 to November 2024 to identify patients with suspected and confirmed cases of EDTA-PCTP. Results: The prevalence rate observed was 0.044% (12 out of 27,480). Additionally, we established that platelet count measurement from the citrate tube at 2–5 h post-sampling was comparable to the platelet count from the EDTA/K2 tube at time 0 (p > 0.05) in these patients. Conclusions: We conclude that a relatively low prevalence of EDTA-PTCP was identified in a population of patients attending an outpatient laboratory in Chile, marking the first report of its kind in our country. Future studies may validate our findings to enhance understanding of EDTA-PTCP, thereby preventing incorrect diagnoses and treatments.